AU2021254415A1 - Methods of treating Severe Acute Respiratory Syndrome - Google Patents

Methods of treating Severe Acute Respiratory Syndrome Download PDF

Info

Publication number
AU2021254415A1
AU2021254415A1 AU2021254415A AU2021254415A AU2021254415A1 AU 2021254415 A1 AU2021254415 A1 AU 2021254415A1 AU 2021254415 A AU2021254415 A AU 2021254415A AU 2021254415 A AU2021254415 A AU 2021254415A AU 2021254415 A1 AU2021254415 A1 AU 2021254415A1
Authority
AU
Australia
Prior art keywords
dantrolene
subject
administering
sars
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021254415A
Other languages
English (en)
Inventor
Adrian HEPNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eagle Pharmaceuticals Inc
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of AU2021254415A1 publication Critical patent/AU2021254415A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021254415A 2020-04-10 2021-04-08 Methods of treating Severe Acute Respiratory Syndrome Pending AU2021254415A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063008529P 2020-04-10 2020-04-10
US63/008,529 2020-04-10
US202063062623P 2020-08-07 2020-08-07
US63/062,623 2020-08-07
PCT/US2021/026303 WO2021207444A1 (en) 2020-04-10 2021-04-08 Methods of treating severe acute respiratory syndrome

Publications (1)

Publication Number Publication Date
AU2021254415A1 true AU2021254415A1 (en) 2022-10-20

Family

ID=75690705

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021254415A Pending AU2021254415A1 (en) 2020-04-10 2021-04-08 Methods of treating Severe Acute Respiratory Syndrome

Country Status (11)

Country Link
US (1) US12582633B2 (https=)
EP (1) EP4132516A1 (https=)
JP (1) JP2023521162A (https=)
KR (1) KR20220167292A (https=)
CN (1) CN115916189A (https=)
AU (1) AU2021254415A1 (https=)
BR (1) BR112022020107A2 (https=)
CA (1) CA3174684A1 (https=)
IL (1) IL296518A (https=)
MX (1) MX2022012707A (https=)
WO (1) WO2021207444A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605364B2 (en) * 2020-04-10 2026-04-21 Eagle Pharmaceuticals, Inc. Methods of treating SARS-CoV-2 infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201417A (en) 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
US11123328B2 (en) 2017-11-14 2021-09-21 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
US12246028B2 (en) 2018-11-27 2025-03-11 Eagle Research Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
US12605364B2 (en) 2020-04-10 2026-04-21 Eagle Pharmaceuticals, Inc. Methods of treating SARS-CoV-2 infections

Also Published As

Publication number Publication date
US12582633B2 (en) 2026-03-24
EP4132516A1 (en) 2023-02-15
WO2021207444A1 (en) 2021-10-14
CA3174684A1 (en) 2021-10-14
US20230149363A1 (en) 2023-05-18
IL296518A (en) 2022-11-01
CN115916189A (zh) 2023-04-04
BR112022020107A2 (pt) 2022-11-29
KR20220167292A (ko) 2022-12-20
MX2022012707A (es) 2023-01-05
JP2023521162A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
KR102233826B1 (ko) 바이러스 감염을 치료하기 위한 티아졸리드 화합물
US12582633B2 (en) Methods of treating severe acute respiratory syndrome
EP4132518B1 (en) Dantrolene for use in methods of treating sars-cov-2 infections
EP4132519A1 (en) Methods of treating coronavirus infections
WO2021207446A1 (en) Methods of treating viral infections
HK40083259B (en) Dantrolene for use in methods of treating sars-cov-2 infections
HK40083259A (en) Dantrolene for use in methods of treating sars-cov-2 infections
KR20210129579A (ko) 사스 코로나바이러스 감염증 치료용 약학적 조성물
HK40090314A (zh) 治疗严重急性呼吸综合征的方法
US20250281576A1 (en) Prophylactic administration method against respiratory virus, comprising administering interferon-beta to potential respiratory virus-infected subject
RU2794315C1 (ru) Способ профилактики или лечения коронавирусной и других острых респираторных вирусных инфекций
KR20220009314A (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 약학 조성물
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
HK40029346B (en) Use of a small molecule inhibitor for treatment of respiratory viral pneumonia
CN110179785A (zh) 魏特酮在制备治疗或预防手足口病药物中的应用